Security key
71722W107
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)
CUSIP: 71722W107
Q1 2023 13F Holders as of 31 Mar 2023
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 30,786,694
- Total 13F value
- $219,689,484
- Share change
- +4,252,423
- Put/Call ratio
- 0.81%
- SEC-reported price per share
- $7.14
- Number of holders
- 83
- Value change
- +$28,315,357
- Number of buys
- 48
- Number of sells
- 34
- Shares outstanding
- 79,611,764
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2023
Institutions
83
Top holders
10
PHAT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Phathom Pharmaceuticals, Inc. SEC filings
Phathom Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 71722W107
Recent filing periods:
Ownership snapshot
Top reported holders of PHAT - Phathom Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Man...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
31 Dec 2022
13F
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences Management, L.P. leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences Management,...
11%
Medicxi Ventures Management (Jers...
3.1%
Invesco Ltd.
2.8%
Avidity Partners Management LP
2.4%
Ensign Peak Advisors, Inc
2.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. |
13F
Company
|
11%
|
$94,328,245
8,407,152 shares
|
— | 31 Dec 2022 |
| Medicxi Ventures Management (Jersey) Ltd |
13F
Company
|
3.1%
|
$27,873,554
2,484,274 shares
|
— | 31 Dec 2022 |
| Invesco Ltd. |
13F
Company
|
2.8%
|
$24,769,821
2,207,649 shares
|
— | 31 Dec 2022 |
| Avidity Partners Management LP |
13F
Company
|
2.4%
|
$21,318,000
1,900,000 shares
|
— | 31 Dec 2022 |
| Ensign Peak Advisors, Inc |
13F
Company
|
2.2%
|
$19,760,563
1,761,191 shares
|
— | 31 Dec 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
2.1%
|
$19,011,516
1,694,431 shares
|
— | 31 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
83
Shares
30,786,694
Rows available
83
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2023 vs Q1 2023 Across Filers
Q1 2023 holders
83
Q1 2023 holders
83
Holder diff
0
| Investor | Q1 2023 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q1 2023 value | Q1 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend